Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03028948
Other study ID # 131403
Secondary ID NCI-2017-00084Pr
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date July 12, 2019

Study information

Verified date February 2023
Source Rutgers, The State University of New Jersey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies how well an interactive tailored website works in promoting sun protection and skin self-check behaviors in patients with stage 0-III melanoma. An internet-based program may help individuals to perform skin self-checks and engage in sun protection behaviors.


Description:

PRIMARY OBJECTIVES: I. To evaluate the impact of the interactive tailored website (ITW) versus usual care on skin self-examination (SSE) and sun protection behaviors among individuals diagnosed with melanoma. SECONDARY OBJECTIVES: I. To examine mediators of the impact of the intervention. The effects of the intervention on SSE and sun protection behaviors will be mediated by melanoma knowledge, self-efficacy for SSE and sun protection behaviors, perceived benefits of SSE and sun protection behaviors, perceived barriers to SSE and sun protection behaviors, and perceived controllability of melanoma. TERTIARY OBJECTIVES: I. To examine moderators of the impact of the intervention. To evaluate whether ITW effects are moderated by the following factors: time since diagnosis, disease stage, age, sex, income, education, Internet experience, distress about melanoma, worry about recurrence, and evaluation and usage of the ITW. OUTLINE: Phase I: Patients review draft website content materials in a semi-structured format and provide feedback via open- and closed-ended questions for the development, testing, and finalization of ITW. Phase II: Patients are randomized into 1 of 2 arms. ARM I: Patients access ITW and complete each module over 30-40 minutes. ARM II: Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 485
Est. completion date July 12, 2019
Est. primary completion date July 12, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Phase I: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma - Phase I: From 3-36 months post-surgical treatment - Phase I: Access to the internet - Phase I: Able to speak and read English - Phase I: Able to provide informed consent - Phase II: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma - Phase II: From 3-24 months post-surgical treatment - Phase II: Not adherent to thorough SSE (i.e., did not check every area of the body at least once during the past 2 months) - Phase II: Not adherent to sun protection recommendations (i.e., mean score < 4 [which corresponds to "often"] on a 5-point scale [from 1 = "never" to 5 = "always"] that assesses the frequency of engaging in four sun protection behaviors) - Phase II: Access to a computer connected to the internet - Phase II: Able to speak and read English - Phase II: Able to provide informed consent

Study Design


Intervention

Other:
Internet-Based Intervention
Access ITW
Questionnaire Administration
Ancillary studies
Survey Administration
Ancillary studies

Locations

Country Name City State
United States University of Virginia Charlottesville Virginia
United States Rutgers Cancer Institute of New Jersey New Brunswick New Jersey

Sponsors (3)

Lead Sponsor Collaborator
Rutgers, The State University of New Jersey National Cancer Institute (NCI), University of Virginia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Distress About Melanoma Level of distress (from 1 = not at all distressed to 10 = extremely distressed) At 8, 24 and 48 weeks
Other Worry About Melanoma Recurrence Mean rating of four questions regarding worry about melanoma recurrence At 8, 24 and 48 weeks
Other Perceived Risk of Melanoma Recurrence Mean rating of four questions regarding perceived risk of melanoma recurrence At 8, 24 and 48 weeks
Other Biopsies Conducted Number of biopsies conducted At 48 weeks
Other Indoor Tanning Number of times indoor tanned in the past year At 48 weeks
Other Diagnosis of New or Recurrent Skin Cancers Whether a new or recurrent skin cancer was diagnosed At 48 weeks
Other Indicators of Study Feasibility Ineligibility rate and reasons, recruitment rate and reasons for refusal, differences in sociodemographic factors between study decliners and those recruited, dropout rate and reasons. At 48 weeks
Other Visits to Healthcare Provider Related to Skin Surveillance Receipt of a physician skin examination and the reason for the visit At 8, 24 and 48 weeks
Other Impact and Effectiveness of the Interactive Tailored Website Perceived Internet Impact and Effectiveness Questionnaire was used. This 20-item survey was used to measure the degree to which MSS helped the participant learn how to be prepared to conduct SSE and engage in sun protection behaviors as well as feel in control of his/her health and feel less worried about melanoma. A Likert scale was used for each question (1=not at all, 2=slightly, 3=somewhat, 4=mostly, 5=very). The scores from each question were averaged to compute the total scale score for each participant. The total scores for each participant were also averaged to find the overall average across MSS participants. Higher values represent greater effectiveness of the program. At 8 weeks
Other Usage of the Interactive Tailored Website Number of visits to the website, the number of monthly skin self-checks completed, the number of updates to the sun-safe action plan, and starting/completing the remaining sections of the website (Introduction; Getting Ready to Do a Skin Self-Check; Practice Sun-Safe Behaviors). At 8, 24 and 48 weeks
Other Evaluation and Utility of the Interactive Tailored Website Internet Evaluation and Perceived Utility Questionnaire and the Internet Adherence Questionnaire was used. This 15-item survey assessed the program characteristics, including usefulness, convenience, ease of use, worry about privacy, ease of navigation, and satisfaction with the program. A Likert scale was used for each question (1=not at all, 2=slightly, 3=somewhat, 4=mostly, 5=very). The scores from each question were averaged to compute the total scale score for each participant. The total scores for each participant were also averaged to find the overall average across MSS participants. Higher values represent higher scores in terms of utility and evaluation of the program. At 8 weeks
Primary Sun Protection Behavior Index Participants rated how often they engaged in four behaviors when outside on a sunny day: wearing sun screen with an Sun Protection Factor = 30, wearing a long-sleeved shirt, wearing a wide-brimmed hat, and staying in the shade. Items were rated on a five-point Likert scale (1=never, 2= rarely, 3= sometimes, 4= often, 5=always). In this case, higher values are associated with more protection behaviors. Subscales were averaged to compute the total index score. At 24 weeks
Primary Number of Participants That Performed a Thorough Skin Self-examination (SSE) in the Past 2 Months Defined as thoroughly examining each area of the body during the most recent skin self-check in the last 2 months. 8 weeks
Secondary Performance of Thorough Skin-self-examination (SSE) in the Past 4 Months Defined as thoroughly examining each area of the body during the most recent skin self-check in the past 4 months At 24 weeks
Secondary Performance of Thorough Skin-self-examination (SSE) in the Past 6 Months Defined as thoroughly examining each area of the body during the most recent skin self-check in the past 6 months 48 weeks
Secondary Number of SSEs Performed Total number of SSEs performed (regardless of their thoroughness) At 8, 24 and 48 weeks
Secondary Number of Body Areas Examined Total number of body areas examined during the most recent SSE in the last 2 months At 8, 24 and 48 weeks
Secondary Use of Tools to Facilitate SSE Use of a mirror, having someone else help, or using a body mole map during the most recent SSE At 8, 24 and 48 weeks
Secondary Frequency of Engaging in Each Individual Sun Protection Behavior From the Sun Protection Behavior Index Frequency (from 1 = never to 5 = always) of wearing sunscreen with an SPF = 30, wearing a long-sleeved shirt, wearing a wide-brimmed hat, and staying in the shade At 8, 24 and 48 weeks
Secondary Number of Sunburns Total number of sunburns received At 8, 24 and 48 weeks
Secondary Wearing Long Pants Frequency (from 1 = never to 5 = always) of wearing long pants At 8, 24 and 48 weeks
Secondary Wearing Sunglasses Frequency (from 1 = never to 5 = always) of wearing sunglasses At 8, 24 and 48 weeks
Secondary Sunbathing Frequency (from 1 = never to 5 = always) of spending time in the sun in order to get a tan At 8, 24 and 48 weeks
Secondary Sun Protection Behavior Index Participants rated how often they engaged in four behaviors when outside on a sunny day: wearing sun screen with an Sun Protection Factor = 30, wearing a long-sleeved shirt, wearing a wide-brimmed hat, and staying in the shade. Items were rated on a five-point Likert scale (1=never, 2= rarely, 3= sometimes, 4= often, 5=always). In this case, higher values are associated with more protection behaviors. Subscales were averaged to compute the total index score. Baseline
Secondary Sun Protection Behavior Index Participants rated how often they engaged in four behaviors when outside on a sunny day: wearing sun screen with an Sun Protection Factor = 30, wearing a long-sleeved shirt, wearing a wide-brimmed hat, and staying in the shade. Items were rated on a five-point Likert scale (1=never, 2= rarely, 3= sometimes, 4= often, 5=always). In this case, higher values are associated with more protection behaviors. Subscales were averaged to compute the total index score. At 8 weeks
Secondary Sun Protection Behavior Index Participants rated how often they engaged in four behaviors when outside on a sunny day: wearing sun screen with an Sun Protection Factor = 30, wearing a long-sleeved shirt, wearing a wide-brimmed hat, and staying in the shade. Items were rated on a five-point Likert scale (1=never, 2= rarely, 3= sometimes, 4= often, 5=always). In this case, higher values are associated with more protection behaviors. Subscales were averaged to compute the total index score. At 48 weeks
See also
  Status Clinical Trial Phase
Completed NCT01886235 - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery N/A
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01989559 - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Phase 1
Withdrawn NCT02812693 - Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Phase 1/Phase 2
Completed NCT02857374 - Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy N/A
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00397982 - Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Phase 2
Terminated NCT01744171 - Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Phase 1
Terminated NCT02748564 - Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT02941744 - A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases Phase 1/Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Terminated NCT02327390 - Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma Phase 1
Active, not recruiting NCT03719131 - Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Phase 2
Active, not recruiting NCT00925314 - A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma Phase 2
Completed NCT00110019 - Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 3
Completed NCT02320305 - MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery Early Phase 1
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Completed NCT00019682 - Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Phase 3
Active, not recruiting NCT03154190 - Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer N/A